CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
H5N1 vaccine plus AS03 adjuvant +1 morebiological
Likely dose
H5N1 vaccine plus AS03 adjuvant 3.75 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01578317
NCT01578317Phase 2Completed

Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Apr 16, 2012·Updated Feb 26, 2019

In Brief

A Phase 2 clinical trial evaluating H5N1 vaccine plus AS03 adjuvant and H5N1 vaccine without adjuvant for Influenza. Completed, enrolled 43 participants across 1 site.

Detailed Summary

Background: \- Adjuvants are substances included in vaccines that stimulate the immune system and increase the body's response to the vaccine. The AS03 adjuvant is used in seasonal flu vaccines in Europe. However, it has not been fully tested in the United States. Researchers want to test the immune responses of people who receive a bird flu vaccine with or without AS03 to better understand how the adjuvant works. This information may help develop better flu vaccines. Objectives: \- To compare the healthy immune system responses to bird flu vaccine with or without the AS03 adjuvant. Eligibility: \- Healthy volunteers between 18 and 45 years of age. Design: * Participants will be screened with a physical exam and medical history. * Participants will be assigned to one of two groups. Each group will have an initial vaccine, followed by a booster vaccine 21 days later. Both vaccinations will use the same type of vaccine. One group will have the vaccine with AS03; the other group will have the vaccine without it. * All participants will have two 36-hour inpatient stays to receive the vaccine. Each stay will involve the vaccination, followed by regular and frequent blood draws. Participants will be monitored for any signs or symptoms that may be caused by the vaccine. * Additional blood samples will be collected 7, 28, 42, and 100 days after the initial vaccination.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 16, 2012
Enrollment StartMar 20, 2012
Primary CompletionJan 31, 2016
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 14.2 years ago

Interventions

H5N1 vaccine plus AS03 adjuvantbiological

H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.

H5N1 vaccine without adjuvantbiological

H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.